CSO Chad Cowan buys 58,060 shares of IPSC at $0.85; holdings now 1,045,087 shares amid +194.8% YoY revenue growth but ongoing losses.
Chad Cowan, Chief Scientific Officer, purchased 58,060 shares at $0.85 on 2025-12-22, increasing holdings to 1,045,087 shares post-transaction. The purchase occurred when IPSC's stock was trading 9.9% below its 52-week high of $1.11 and near recent price momentum (+83.4% over 30 days, +100.8% over 90 days). Century Therapeutics is growing top-line revenue substantially at +194.8% annual growth with a recent quarter revenue of $109,164,000, but remains unprofitable with full-year net income of $-34,422,000 and a market cap of $87,307,091—a company where cash burn and growth dynamics are critical to valuation. The insider's accumulation of 58,060 shares (5.9% increase in holdings) during a period of strong recovery from 52-week lows may reflect assessment of company fundamentals, though investors should scrutinize whether profitability timelines and burn rate justify current valuations.